|Articles|March 15, 2005

2005 ACT Directory and Buyers Guide

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

ByRob DiCicco

July 2nd 2026

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

ByAndy Studna, Senior Editor

July 2nd 2026

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

ByElizabeth Walsh, PMP, ACRP-CP

July 1st 2026

The Data Behind Reducing Trial Burden Without Sacrificing Quality

ByRob DiCicco,Andy Studna, Senior Editor

July 1st 2026

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

ByAndy Studna, Senior Editor

July 1st 2026

2005 ACT Directory and Buyers Guide

Related Content

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

The Data Behind Reducing Trial Burden Without Sacrificing Quality

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

Trending on Applied Clinical Trials Online

NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

ACT Brief: Real-Time Trial Infrastructure Gaps, Built-In Data Security, and AI-Enabled CDMO Value

Real-Time Clinical Trials: What the FDA's Push Toward Continuous Oversight Means for Sponsors